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Introduction
Surgical treatment of unilateral laryngeal paralysis is based
on three procedures: thyroplasty, which may be associated
to arytenoid adduction; medialization by intracordal injec-
tion; and reinnervation. Injection medialization has been
revived by the advent of new methods of percutaneous
injection by cervical route under local anesthesia. Such
minimally invasive methods allow ambulatory management
and are suitable for more fragile patients [1—3]. They were
developed following improvements in ﬁlling materials in
plastic surgery: the international literature abounds in
materials with varying pharmacologic properties and life
expectancies. The present study is an update on the cordal
medialization ﬁllers available in France in 2010.∗ Corresponding author.
E-mail address: aude.lagier@ap-hm.fr (A. Lagier).
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review was performed on the international literature
or the period 2001—2010. The articles studied described
echniques of medialization by injection of exogenous
ubstances, whatever the injection method (laryngoscopy,
ervical route or nasoﬁbroscopy). The list of substances
etrieved was then compared to the French health products
afety agency (AFSSAPS) data.
esults and discussion
he list of products found in the literature and their
haracteristics is shown in Table 1.
The development of these cordal medialization ﬁllers
s promising for ambulatory management of unilateral
aryngeal paralysis. Several substances have been used
or vocal fold augmentation, but in France at present
nly polydimethylsiloxane (Vox Implant®, Medtronic,
rance) is available (ofﬁcial marketing authorization [MA])
or medialization by intracordal injection. Injection is
erformed under direct laryngoscopy; the percutaneous
.
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Table 1 List and life expectancies of substances described in the literature and French Marketing Authorizations (MA).
Material (nature and
brand-name)
Possible injection
modalities
Life expectancy MA in laryngology MA in plastic surgery
Silicone (Vox
Implant®) [4,5]
Suspension
laryngoscopy
Deﬁnitive Yes No
Bovine collagen
(Zyplast®) [1]
Suspension
laryngoscopy, cervical
route
Short: 3 to 6 months MA in laryngology, but
marketing stopped in
France in 2010
Human collagen
(Cymétra®,
Cosmoderm®,
Cosmoplast®)
[1,3,6]
Suspension
laryngoscopy, cervical
route
Short: 3 to 6 months Not available in France
Calcium
hydroxyapatite
(Radiesse®) [6,7]
Suspension
laryngoscopy, cervical
route ±
Long: 6 to 24 months No Yes
Hyaluronic acid large
particles (Perlane®)
[8]
Suspension
laryngoscopy, cervical
route
Long: 6 to 24 months No Yes
Hyaluronic acid Small
particles
(Restylane®,
Hylaform®) [1,3]
Suspension
laryngoscopy, cervical
route
Short: 3 to 6 months No Yes
Polyacrylamide
hydrogel
(Aquamid®) [9]
Suspension
laryngoscopy, cervical
route
Deﬁnitive No Yes
Bovine gel (Gelfoam®
poudre) [10]
Cervical route,
naso-ﬁbroscopy
Very short: 1 to 3 months No
Used in surgery
(hemostasis)
Methylcellulose
(Radiesse voice
Suspension
laryngoscopy, cervical
Very short: 1 to 3 months Not available in France
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MA: Marketing authorization.
ervical attitude is inappropriate here due to the very
ong life expectancy of silicone, making any malpositioning
rreversible [7]. Injection should be very deep into the
hyroarytenoid muscle in the paraglottic space.
Collagen has no longer been marketed in France since the
ummer of 2010. Bovine collagen (Zyplast®) required per-
orming a test dose to the forearm to rule out allergy. There
as a risk of autoimmune disease such as dermatomyositis
r polymyositis. No complications were reported with pro-
essed human collagen (Cymetra®, Cosmoderm®), but this
s not available on the French market.
Fillers developed for esthetic applications, such as
olyacrylamide hydrogel (Aquamid®, FerrosanA/S) [9],
yaluronic acid (Perlane®, Restylane®, Hyladerm®®) [8],
r calcium hydroxyapatite (Radiesse®) [6,7], were used
ith success by certain authors, but do not come in a form
uitable for laryngology (no MA for this indication).
Methylcellulose exists in a form suitable for laryngology
nd is authorized in certain countries but not in France (no
A for this indication).
®Finally the rapid resorption characterizing Gelfoam
Gelfoam®, Pﬁzer, France) in the form of a paste reconsti-
uted from powder would make it an interesting ﬁller in case
f recent paralysis with unpredictable evolution: compensa-
ion by the healthy contralateral vocal fold or spontaneouseinnervation could be expected, but again this substance
as no MA in this indication [10].
Market authorization for these resorbable products in
rance would enable ambulatory management of laryngeal
aralysis, and the consequent prevention of inhalation pneu-
opathy would doubtless have a positive impact on health
osts. At the present time, the cost of Vox Implant® is to
e weighed against that of other medialization techniques
sing autologous material (fat, fascia temporalis) or of thy-
oplasty; comparison should also take surgery time (and
ence theater costs) into account.
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